GlassScriptPhysician profile
Matthew Johnston
NPI 1447467170
$11,951.31
in general payments reported to CMS, 2019-2025
34 companies · $898 in 2025
The $898 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $258 · 2021: $7,553 · 2022: $1,532 · 2023: $269 · 2024: $648 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.05 |
| Travel and Lodging | $427.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $7,346.38 | 2021-2024 | Aponvie, Zynrelef |
| Reel Surgical, INC. | $1,371.42 | 2022-2025 | |
| Zimmer Biomet Holdings, INC. | $653.12 | 2019-2025 | Mymobility Platform, Juggerknotless Soft Anchor, Taperloc |
| Arthrex, INC. | $471.35 | 2024 | |
| Smith+Nephew, INC. | $218.68 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System, Bioinductive Implant With Arthroscopic Delivery System - Medium, Q-Fix |
| Integra Lifesciences Corporation | $170.60 | 2022 | |
| Stryker Corporation | $165.09 | 2019 | |
| Horizon Therapeutics Plc | $155.17 | 2019 | |
| Bioventus LLC | $151.15 | 2019-2025 | Xcell, Supartz Fx Sodium Hyaluronate, L360 Thigh System |
| Innovation Technologies INC | $136.52 | 2020 | |
| Ferring Pharmaceuticals INC. | $135.52 | 2019-2025 | Euflexxa |
| Pacira Pharmaceuticals Incorporated | $101.30 | 2020-2025 | Exparel, Zilretta, Iovera |
| Zyla Life Sciences, INC. | $96.64 | 2019-2020 | |
| Theragen, INC. | $91.20 | 2021 | |
| Electronic Waveform Lab, INC. | $88.94 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $67.20 | 2025 | |
| Vericel Corporation | $64.11 | 2023-2024 | Maci |
| Anika Therapeutics, INC. | $56.43 | 2023 | Tactoset, Ovomotion |
| Pacira Therapeutics, INC. | $50.51 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $49.91 | 2025 | |
| Heraeus Medical, LLC. | $40.47 | 2021-2025 | |
| Medacta USA, INC. | $34.18 | 2019 | |
| Highridge Medical LLC | $28.02 | 2024 | Biomet Ebi Bone Healing System |
| Carbofix Orthopedics INC | $27.41 | 2022 | |
| Kerecis Limited | $24.81 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Edwards Lifesciences Corporation | $22.49 | 2023 | Sapien 3 Ultra Resilia |
| Ermi LLC | $21.25 | 2019 | |
| Abbott Laboratories | $17.69 | 2025 | Eterna |
| Amgen INC. | $17.65 | 2025 | Evenity |
| Karl Storz Endoscopy-America | $17.14 | 2019 | |
| Depuy Synthes Sales INC. | $16.71 | 2021 | |
| Ethicon US, LLC | $14.98 | 2019 | |
| Dynasplint Systems INC. | $14.34 | 2019 | |
| Bolder Surgical LLC | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.